An Open-label, Randomized, Single Dose, Multi-stage, Cross-over Study to Determine the Relative Bioavailability of Fixed Dose Combination Products Containing a 3-oblong Dutasteride Soft Gel Capsule and Tamsulosin (0.5 mg Dutasteride /0.2 mg Tamsulosin HCl) Pellets Having a Range of Tamsulosin Release Rates Produced by Different Mixtures of Enteric Coated and Uncoated Pellets Relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian Ancestry.
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Dutasteride/tamsulosin (Primary) ; Dutasteride; Tamsulosin
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 23 Dec 2011 New trial record